NiCCC

Trial Description: 
A Randomised Phase II Study Of Nintedanib (BIBF1120) Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium
Lead Cooperative Group: 
Participating Groups: 
Disease Site: 
Recurrent Ovarian / Rare
Trial Status: 
Recruiting
Contact person: